Patterns of infection in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) receiving 5-azacitidine. Candidates for antifungal prophylaxis

被引：0
|
作者：
Falantes, J. [1 ]
Calderon, C. [1 ]
Marquez-Malaver, F. J. [1 ]
Aguilar, M. [2 ]
Martino, M. L. [1 ]
Gonzalez, J. [1 ]
Montero, M. I. [1 ]
Parody, R. [1 ]
Espigado, I. [1 ]
Perez-Simon, J. A. [1 ]
机构：
[1] Hosp Virgen Rocio, Hematol, Inst Biomed Sevilla IBIS, Seville, Spain
[2] Hosp Virgen Rocio, Infect Dis, Seville, Spain
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70043-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-021
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [21] BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
    Vidal, Valerie
    Ginet, Clemence
    Karsenti, Jean Michel
    Luciano, Frederic
    Gastaud, Lauris
    Garnier, Georges
    Braun, Thorsten
    Hirsch, Pierre
    Raffoux, Emmanuel
    Nloga, Anne Marie
    Dombret, Herve
    Rohrlich, Pierre-Simon
    Ades, Lionel
    Chomienne, Christine
    Fenaux, Pierre
    Auberger, Patrick
    Robert, Guillaume
    Cluzeau, Thomas
    BLOOD, 2014, 124 (21)
  • [22] REDIFINING MONOSOMY 20 BY MOLECULAR CYTOGENETICS IN 1.0 MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA (MDS/AML) PATIENTS
    Bernasconi, P.
    Dambruoso, I.
    Boni, M.
    Zappatore, R.
    Cavigliano, P. M.
    Giardini, I.
    Calatroni, S.
    Rocca, B.
    Caresana, M.
    Tarantino, P.
    Lazzarino, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 273 - 273
  • [23] Low dose Vidaza and thalidomide is an effective combination for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Westervelt, P.
    Amirifeli, S.
    Mehdi, M.
    Mumtaz, M.
    Alhomsi, S.
    Wang, S.
    Miron, P.
    Lata, C.
    Galili, N.
    Raza, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 354S - 354S
  • [24] SINGLE INSTITUTION EXPERIENCE OF 5-AZACITIDINE THERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
    Freyrie, A.
    Guidotti, F.
    Reda, G.
    Binda, F.
    Cortelezzi, A.
    HAEMATOLOGICA, 2012, 97 : 587 - 587
  • [25] CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
    William, Basem M.
    de Lima, Marcos
    Oran, Betul
    Champlin, Richard
    Papadopoulos, Esperanza B.
    Giralt, Sergio
    Scott, Bart L.
    Hetzer, Joel
    Wang, Xiwei
    Laille, Eric
    Skikne, Barry S.
    Craddock, Charles
    BLOOD, 2014, 124 (21)
  • [26] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [27] ASSESSMENT OF INFECTION EVENTS IN AZACITIDINE (AZA) TREATMENT FOR MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE MYELOID LEUKEMIA (AML). A SINGLE CENTRE EXPERIENCE.
    Romero, P.
    Borras, J. B.
    Serra, F.
    Nigorra, M.
    Del Campo, R.
    Cladera, A.
    Vazquez, I.
    Mascaro, M.
    Gonzalez, E.
    Guerra, J. M.
    Gomez, D.
    Bargay, J.
    HAEMATOLOGICA, 2014, 99 : 196 - 196
  • [28] EXTRAMEDULLARY LEUKEMIA (EML) IN MYELODYSPLASTIC SYNDROMES (MDS) - NOT A TRUE INDICATION OF IMPENDING ACUTE MYELOID-LEUKEMIA (AML)
    EDENFIELD, WJ
    BYRD, JC
    AYLESWORTH, C
    DOW, NS
    DAWSON, N
    BLOOD, 1994, 84 (10) : A631 - A631
  • [29] EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE
    Savona, M. R.
    Kolibaba, K.
    Conkling, P.
    Kingsley, E. C.
    Becerra, C.
    Morris, J. C.
    Rifkin, R. M.
    Laille, E.
    Kellerman, A.
    Ukrainskyj, S. M.
    Dong, Q.
    Skikne, B. S.
    LEUKEMIA RESEARCH, 2015, 39 : S29 - S30
  • [30] ROLE OF ANTIMICROBIAL PROPHYLAXIS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA RECEIVING AZACITIDINE THERAPY
    Avila, F.
    Lorenzana, N.
    Alonso, S.
    Colado, E.
    Bernal, T.
    LEUKEMIA RESEARCH, 2017, 55 : S160 - S160
12345